CMMB vs. EYEN, VYNE, FBIO, MRKR, LPCN, CARA, UNCY, PMN, RNXT, and BOLT
Should you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Eyenovia (EYEN), VYNE Therapeutics (VYNE), Fortress Biotech (FBIO), Marker Therapeutics (MRKR), Lipocine (LPCN), Cara Therapeutics (CARA), Unicycive Therapeutics (UNCY), ProMIS Neurosciences (PMN), RenovoRx (RNXT), and Bolt Biotherapeutics (BOLT). These companies are all part of the "pharmaceutical preparations" industry.
Eyenovia (NASDAQ:EYEN) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation.
Eyenovia received 153 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. Likewise, 65.13% of users gave Eyenovia an outperform vote while only 62.96% of users gave Chemomab Therapeutics an outperform vote.
Eyenovia presently has a consensus price target of $10.00, indicating a potential upside of 1,137.62%. Chemomab Therapeutics has a consensus price target of $5.67, indicating a potential upside of 429.60%. Given Chemomab Therapeutics' higher probable upside, analysts clearly believe Eyenovia is more favorable than Chemomab Therapeutics.
In the previous week, Eyenovia and Eyenovia both had 2 articles in the media. Eyenovia's average media sentiment score of 1.59 beat Chemomab Therapeutics' score of 1.58 indicating that Chemomab Therapeutics is being referred to more favorably in the news media.
25.8% of Eyenovia shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 7.1% of Eyenovia shares are held by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Eyenovia has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.
Eyenovia is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.
Eyenovia's return on equity of -109.92% beat Chemomab Therapeutics' return on equity.
Summary
Chemomab Therapeutics beats Eyenovia on 9 of the 14 factors compared between the two stocks.
Get Chemomab Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chemomab Therapeutics Competitors List
Related Companies and Tools
